Pediatric Pharmacy Specialty Review Course for Recertification, Core Therapeutic Modules + RECERT EXAMS Package (Cert # L229268)

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in pediatric pharmacy.

This course consists of 11 activities (see table below) and provides up to 16 contact hours of continuing pharmacy education credit. The review course includes case-based presentations for application to real-life scenarios, a practice exam along with correct answers, and links to the reference sources, and domains, tasks, and knowledge statements. To help you further prepare, this package includes a compilation of practice questions in the same format and rigor to help you prepare for the BPS Specialty Examination.

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

At the end of the presentations, the pharmacist should be able to:                                                   

Complex Case: Deep Vein Thrombosis and Metabolic Syndrome
ACPE #: 0204-0000-22-620-H01-P

• Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including deep vein thrombosis, type 2 diabetes mellitus, dyslipidemia, and hypertension.
• Identify resources and treatment options for sexually transmitted infections.
• Select appropriate monitoring considerations of anticoagulation medications.
• Recognize the impact of pharmacogenomic differences on warfarin therapy. 

Complex Case: Diabetic Ketoacidosis
ACPE #: 0204-0000-22-621-H01-P

• Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including diabetic ketoacidosis, type 1 diabetes mellitus, and urinary tract infection.
• Calculate maintenance and replacement fluid requirements and urine output.
• Identify factors affecting medication adherence.
• Recommend appropriate dosing of insulin based on patient age and weight.
• Select an effective method of delivery for insulin. 

Complex Case: Acute Asthma
ACPE #: 0204-0000-22-622-H01-P

• Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including acute and chronic asthma, ADHD, acne and GERD.
• Evaluate essential components of social history, including smoke exposure and home environment.
• Formulate a plan to address barriers to patient education and adherence, including age, language, cultural considerations, and inhaler technique.
• Describe the impact of age on classification and management of asthma.
• Assess available resources to improve access to medications, including patient assistance programs. 

Complex Case: Pneumonia and Septic Shock
ACPE #: 0204-0000-22-623-H01-P

• Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including pneumonia, septic shock, and acute kidney injury.
• Calculate creatinine clearance, fluid requirements, and urine output in pediatric patients.
• Apply scoring systems to assess pediatric patients.
• Select appropriate dosing for medications based on renal dysfunction and/or replacement modalities.
• Differentiate vital signs between stable and critically-ill pediatric patients. 

Complex Case: Acute Lymphoblastic Leukemia with Tumor Lysis Syndrome
ACPE #: 0204-0000-22-624-H01-P

• Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including acute lymphoblastic leukemia (ALL), tumor lysis syndrome, febrile neutropenia, invasive aspergillosis infection, and Clostridium difficile infection.
• Select appropriate medication dose modifications related to hepatic impairment. 

Regulatory and IRB Considerations
ACPE #: 0204-0000-22-625-H03-P

• Identify appropriate off-label use of medications in the pediatric population.
• Recognize IRB requirements for documentation of clinical studies.
• List characteristics of patients who require informed assent/consent.
• Recognize federal legislation relevant to the use of medications in pediatric patients. 

Complex Case:  Sickle Cell Disease with Vaso-Occlusive Crisis
ACPE #: 0204-0000-22-626-H01-P

• Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions, including a vaso-occlusive crisis, cellulitis, constipation, and need for immunizations.
• Select most appropriate patient controlled analgesia regimen based on vaso-occlusive crisis severity.
• Apply pharmacodynamic principles when selecting appropriate antibiotic regimens.
• Identify required immunizations for adolescents, including patients with risk factors for vaccine-preventable diseases. 

Medication Error and Practice Management
ACPE #: 0204-0000-22-627-H05-P

• Incorporate position statements, white papers, national guidelines from recognized regulatory organizations into institutional policies and procedures related to:
  • Medication reconciliation
  • Appropriate drug preparation and delivery (e.g., extemporaneous compounding and standardized concentrations)
  • Selection of appropriate equipment/technology and decision support.
  • Adverse drug event monitoring and reporting, or
  • Metrics for evaluating quality of pediatric pharmacy services. 

Complex Case: Neonatal Sepsis
ACPE #: 0204-0000-22-628-H01-P

• Develop appropriate treatment and monitoring plans for a complex neonatal patient with multiple conditions, including patent ductus arteriosus, apnea of prematurity, early and late onset sepsis, and necrotizing enterocolitis.
• Evaluate the clinical and therapeutic implications of placental transfer of medications.
• Identify age-specific pharmacokinetic differences among neonates, infants, children, and adolescents.
• Apply FDA alerts for adverse drug events and drug-drug interactions into clinical practice.
• Identify characteristics that facilitate transfer of medications into the breast milk. 

Complex Case: Status Epilepticus and Cardiopulmonary Resuscitation
ACPE #: 0204-0000-22-629-H01-P

• Develop appropriate treatment and monitoring plans for a complex pediatric patient with multiple conditions and needs, including status epilepticus, cardiopulmonary resuscitation, and sedation/analgesia.
• Differentiate treatment options in cardiopulmonary arrest based upon patient presentation.
• Select the appropriate dose and route of administration for medications.
• Assess the need and processes for reporting adverse drug events.
• Identify cultural considerations related to treatment and counseling of the pediatric population.
• Distinguish between the four preceptor roles. 

Statistics, Evidence-Based Medicine, and Clinical Trial Design
ACPE #: 0204-0000-21-985-H04-P

• Interpret biomedical literature with regard to study design, methodology, statistical analysis, and significance and applicability of reported data and conclusions.
• Explain the use of evidence-based treatment guidelines and protocols.
• Summarize key points from the most current pharmacy practice literature.

The Core Therapeutic Modules Review Package consists of 3 activities in which faculty review clinical topics and practice skills using a case-based approach. And provides up to 3 contact hours of continuing pharmacy education credit. The activities are designed to assist the learner in identifying knowledge gaps in preparation for a pharmacy specialty board examination. In addition to a recorded presentation, each activity includes links to resources for further self-study and a practice test developed in the same format and rigor as the specialty exam. 

After participating in these CPE activities, learners should be able to:

Select Topics in Pediatric Cardiovascular Disease
ACPE #: 0204-0000-22-630-H01-P

• Interpret signs, symptoms and diagnostic tests in a pediatric patient with congenital heart disease (specifically VSD, ASD, TOF, coarctation of aorta, and hypoplastic left heart) or Kawasaki disease.
• Identify drug-related problems, including drug interactions.
• Develop the most appropriate therapy and monitoring plans based on patient-specific information and the most current guidelines.
• Use PALS to determine appropriate therapy for bradycardia and tachycardia. 

Select Topics in Pediatric Infectious Diseases Part 1
ACPE #: 0204-0000-22-631-H01-P

• Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a well-appearing febrile infant.
• Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with otitis media.
• Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with bronchiolitis.
• Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with tuberculosis.
• Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with meningitis.
• Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with pneumonia.

Select Topics in Pediatric Neurology Part 2 - Focus on Seizures
ACPE #: 0204-0000-22-632-H01-P

• Develop treatment and monitoring plans based on patient-specific information and the most current guidelines for a pediatric patient with febrile seizures, neonatal seizures, infantile spasms, absence seizures, and Lennox-Gastaut syndrome.
• Evaluate patients for drug-related problems.
• Identify appropriate modifications of patient-specific treatment plans based on follow up assessment. 

Teia Brandenburg, PharmD, BCPPS
Clinical Pharmacist – Child Neurology
University of Kentucky Healthcare
Lexington, Kentucky 

Kaitlin Hughes, PharmD, BCPPS
Clinical Pharmacist Pediatric Critical Care
Riley Hospital for Children at IU Health
Indianapolis, Indiana 

Peter N. Johnson, PharmD, BCPPS, BCPS, FCCM, FPPAG
Professor of Pharmacy Practice
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma 

Michelle Kussin, PharmD, BCOP
Clinical Pharmacist, Pediatric Infectious Diseases
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana 

Kevin Lonabaugh, PharmD, BCACP, AAHIVP, AE-C
Clinical Pharmacist - Pediatric Ambulatory Care
University of Virginia Children’s Hospital
Charlottesville, Virginia 

Mya Merrow, PharmD, BCOP
Pediatric Oncology Clinical Pharmacist
Children's Hospital Colorado
Aurora, Colorado 

Rachel S. Meyers, PharmD, BCPPS, BCPS, FPPAG
Clinical Associate Professor
Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey
Piscataway, New Jersey
Pediatric Pharmacist
Saint Barnabas Medical Center
Livingston, New Jersey 

Jamie L. Miller, PharmD, BCPPS, BCPS, FPPAG*
Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma 

Jill Morgan, PharmD, BCPPS, BCPS
Professor and Chair
University of Maryland School of Pharmacy
Baltimore, Maryland 

Ashley Nebbia, PharmD, BCCPS
Emergency Medicine Clinical Pharmacist
Golisano Children’s Hospital of SW Florida
Fort Myers, Florida 

Jennifer Thackray, PharmD, BCPPS, BCPS*
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York 

Lisa Thames, PharmD, BCPS
Assistant Director, Inpatient Pharmacy Services
UF Health Shands Hospital
Gainesville, Florida 

*Content matter experts

Michelle Abalos, PharmD
Susan R. Dombrowski, MS, RPh
Kristi Hofer, PharmD

Hakeem Abayomi, BSc, PharmD, BCPS, BCPPS, BCIDP
Leanna Barker, PharmD, BCPPS
Emily Barlow, PharmD, BCPPS
Mei Bell, PharmD, BCPS
Jessica Bergsbaken, PharmD, BCPPS
Monica Bogenschutz, PharmD, BCPS, BCPPS
Olivia Brandner, PharmD, BCPPS
Amber Brax, PharmD, BCPPS
Jordan Burdine, PharmD, MBA, BCPPS
Jeff Butler, PharmD, BCPPS
Melissa Cook, PharmD, BCPPS
Aaron Cooper, PharmD, BCPPS
Jesse Cramer, PharmD, BCPPS
Mackenzie DeVine, PharmD, BCPPS
Darrin Dillingham, PharmD, BCPPS
Charisa Flaherty, PharmD, BCPPS
Jessica  Frye, PharmD, BCPPS
Sarah Hale, PharmD, BCPPS, BCPS
Samantha  Hanna, PharmD, BCPPS
Tina Hellauer, PharmD, BCPPS
Amy Holmes, PharmD, BCPPS, FPPA
Katie Hughes, PharmD, BCPPS
Jin  Kim, PharmD, BCPPS
Ashley Lange , PharmD, BCPPS
Ann Lieb, PharmD, BCPPS
Kristin Luckeroth, PharmD, BCPPSJulie
Miller, PharmD, BCPPS
Macy Miller, PharmD, BCPPS
Erin  Munsel, PharmD, BCPPS
Ashley Nebbia, PharmD, BCPPS
Lane Nguyen, PharmD, BCPPS
Seema Patel, PharmD, MMI, BCPPS, APhA
Tasha Porter, PharmD, BCPPS
Allison  Provine, PharmD, BCPS, BCPPS
Karla Resendiz, PharmD, BCPPS, BCCCP
Anna Simmont, PharmD, BCPS, BCPPS
Tara Smith, PharmD, BCPPS
Sylvia Stoffella, PharmD, BCPPS
Jon Swanson, PharmD, BCPPS
Susan Villegas, PharmD, BCPPS
Aspen Wall, PharmD, BCPPS
Lynn Warner, PharmD, BCPPS
Stephanie Weightman, PharmD, BCPS, BCPPS

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity. 

All other planners, presenters, and reviewers of this session report no financial relationships relevant to this activity. 

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP.